The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.

The DREAMM-7 trial shows belantamab mafodotin combined with bortezomib and dexamethasone significantly improves overall ...

Merck has announced that the Phase 3 KEYLYNK-001 trial demonstrated that KEYTRUDA® (pembrolizumab) combined with chemotherapy ...

Adding BLINCYTO® (blinatumomab) to chemotherapy significantly improves three-year disease-free survival (96%) in children ...

Durvalumab (Imfinzi) has received Priority Review from the FDA for muscle-invasive bladder cancer (MIBC). Backed by positive ...

FDA has granted accelerated approval to Bizengri® (zenocutuzumab-zbco), a first-in-class bispecific antibody targeting NRG1+ ...

Recursion, has dosed the first patient in its Phase 1/2 DAHLIA clinical trial of REC-1245, a potential first-in-class therapy ...

FDA has approved Durvalumab (Imfinzi) as the first and only immunotherapy for adult patients with limited-stage small cell ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for advanced NSCLC with EGFR ...